A novel class of anti-tb drug candidate targeting dpre1 enzyme
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Poster
- By: YU, Luoting (National Key Laboratory of Biotherapy of Sichuan University, Chengdu, China)
- Co-author(s): Wei, Yuquan (National Key Laboratory of Biotherapy of Sichuan University, Chengdu, China)
Tuberculosis remains a significant infectious disease and the emergence of MDR, XDR and TDR strains has worsened the global burden. There is an urgent need to identify new drug targets and obtain new inhibitors. DprE1 enzyme is a key enzyme for the synthesis of the arabinan which is a necessary component of synthesizing the M. tuberculosis cell.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.